Cosmetic surgery practice’s stem cell use runs afoul of FDA

The U.S. Food and Drug Administration has cited a plastic surgery practice over several violations tied to its use of adult stem cells for breast augmentation and other procedures to manufacturing violations.

In a warning letter to Dr. Thomas E. Young, the owner and medical director of Young Medical Spa, the FDAs Center for Biologics Evaluation and Research said the company had significantly altered adult stem cells as part of the process of converting them from adipose tissue.

The FDA allows companies to derive adult stem cells from structural and adipose tissue on condition that the structure of the stem cells is not significantly changed. It permits the use of stem cells to be derived from adipose tissue from one person and injected back into the same person. If the regulator concludes the process significantly changes the adipose tissue, it considers it a biological product that has a much more rigorous set of criteria to meet.

Advertisement

The company singled out a product it uses in breast augmentation procedures containing adipose-derived stem cells as a violation of the regulators rules.

During a factory inspection of the practices Lansdale, Pennsylvania and South Center Valley, Pennsylvania offices between December 2011 and January this year, the regulator said it found numerous violations of good manufacturing and good tissue practices. Among the violations listed in the letter were its failure to keep a record of investigations into cases in which patients experienced adverse reactions. It also did not ensure appropriate laboratory testing of each batch of drug product required to be free of objectionable microorganisms, the letter posted on the regulators website said.

In at least six cases, the letter said, the company failed to investigate adverse reactions such as fever, redness, soreness, cyst formation, mastitis and infection following the procedures.

If the company fails to adequately respond to the FDAs letter, it could lead to regulatory action being taken without further notice. That action could include seizure and/or injunction, the letter said.

The FDAs action follows a letter sent to New York-based IntelliCell BioSciences in March raising some of the same concerns with the stem cell company and would seem to reflect a crackdown by the regulator.

Read the rest here:
Cosmetic surgery practice’s stem cell use runs afoul of FDA